Wassim Elyaman

Dr. Wassim Elyaman


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2022 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
CRChunsheng Ruan
Chunsheng Ruan
WEWassim Elyaman
Wassim Elyaman
A New Understanding of TMEM119 as a Marker of Microglia

1 January 2020 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
CRChunsheng Ruan
Chunsheng Ruan
LSLinlin Sun
Linlin Sun
AKAlexandra Kroshilina
Alexandra Kroshilina
LBLien Beckers
Lien Beckers
PJPhilip De Jager
Philip De Jager
WEWassim Elyaman
Wassim Elyaman

2 November 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
EKEsilida Sula Karreci
Esilida Sula Karreci
SESiawosh K. Eskandari
Siawosh K. Eskandari
Farokh Jal DotiwalaFarokh Jal Dotiwala
Farokh Jal Dotiwala
SRSujit K. Routray
Sujit K. Routray
AKAhmed T. Kurdi
Ahmed T. Kurdi
JAJamil Azzi
Jamil Azzi
Tregs hold great promise as a cellular therapy for multiple immunologically mediated diseases, given their ability to control immune responses. The success of such strategies depends on the expansion of healthy, suppressive Tregs ex vivo and in vivo following the transfer. In clinical studies, levels of transferred Tregs decline sharply in the blood within a few days of the transfer. Tregs have a high rate of apoptosis. Here, we describe a new mechanism of Treg self-inflicted damage. We show that granzymes A and -B (GrA and GrB), which are highly upregulated in human Tregs upon stimulation, leak out of cytotoxic granules to induce cleavage of cytoplasmic and nuclear substrates, precipitating apoptosis in target cells. GrA and GrB substrates were protected from cleavage by inhibiting granzyme activity in vitro. Additionally, we show — by using cytometry by time of flight (CYTOF) — an increase in GrB-expressing Tregs in the peripheral blood and renal allografts of transplant recipients undergoing rejection. These GrB-expressing Tregs showed an activated phenotype but were significantly more apoptotic than non–GrB expressing Tregs. This potentially novel finding improves our understanding of Treg survival and suggests that manipulating Gr expression or activity might be useful for designing more effective Treg therapies.

16 January 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TBThomas S. Buttrick
Thomas S. Buttrick
WWWei Wang
Wei Wang
CYChristina Yung
Christina Yung
KTKenneth G. Trieu
Kenneth G. Trieu
KPKruti Patel
Kruti Patel
WEWassim Elyaman
Wassim Elyaman
T helper 9 (Th9) cells are effector CD4+ T cells that are characterized by the production of interleukin-9 (IL-9) and have been associated with allergic responses. Here, we found that the expression of the transcription factor forkhead box O1 (Foxo1) was induced in Th9 and Foxo1 plays a crucial role in the differentiation of Th9 cells. Pharmacological inhibition of Foxo1 or genetic disruption of Foxo1 in CD4+ T cells caused a reduction in IL-9 expression while upregulating IL-17A and IFNγ production. Furthermore, chromatin immunoprecipitation (ChIP) followed by luciferase assays revealed direct binding of Foxo1 to both the Il9 and Irf4 promoters and induces their transactivation. Lastly, adoptive transfer of Th9 cells into lungs induced asthma-like symptoms that were ameliorated by Foxo1 inhibitor, AS1842856. Together, our findings demonstrate a novel regulator of Th9 cells with a direct implication in allergic inflammation.

27 January 2026 in Nature Immunology
Verified
Journal Article
Open access
PDF file
RHRyan Hobson
Ryan Hobson
SLSamuel H. S. Levy
Samuel H. S. Levy
CSChitra Mohinder Singh Singal
Chitra Mohinder Singh Singal
DFDelaney Flaherty
Delaney Flaherty
HXHarrison Xiao
Harrison Xiao
WEWassim Elyaman
Wassim Elyaman
Meningeal immune cells monitor the central nervous system (CNS) and influence neuroinflammation in mice, but the human leptomeningeal immune landscape and the changes that occur in this immunological niche in neurodegeneration remain underexplored. Here we performed single-cell RNA and T cell receptor (TCR) sequencing of 99,625 high-quality immune cells from 57 leptomeninges and brain samples from donors with Alzheimer’s disease (AD), amyotrophic lateral sclerosis and Parkinson’s disease and found that although the leptomeninges are home to highly clonally expanded CD8 tissue-resident memory (TRM) T cells, the maximal level of clonal expansion was decreased in AD in comparison to non-neurodegenerative controls. Intra-patient paired tissue analysis further revealed that brain and leptomeningeal TCR repertoires share significant similarities, but tissue-specific clones emerge in AD. Finally, in AD, the degree of CD8 TRM clonal expansion was positively correlated with microglial TGFB2, suggesting that brain and leptomeningeal immune cells coordinate their activities in AD. In addition to identifying key inflammatory dynamics in the human degenerating CNS, this study establishes a foundational resource for future studies that could inform treatment for AD and other neuroinflammatory diseases.

27 January 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
WEWassim Elyaman
Wassim Elyaman
LSLawrence J. Stern
Lawrence J. Stern
NJNing Jiang
Ning Jiang
DDDallin Dressman
Dallin Dressman
PBPhilip Bradley
Philip Bradley
SPSerge Przedborski
Serge Przedborski
This proceedings article summarizes the inaugural “T Cells in the Brain” symposium held at Columbia University. Experts gathered to explore the role of T cells in neurodegenerative diseases. Key topics included characterization of antigen‐specific immune responses, T cell receptor (TCR) repertoire, microbial etiology in Alzheimer's disease (AD), and microglia–T cell crosstalk, with a focus on how T cells affect neuroinflammation and AD biomarkers like amyloid beta and tau. The symposium also examined immunotherapies for AD, including the Valacyclovir Treatment of Alzheimer's Disease (VALAD) trial, and two clinical trials leveraging regulatory T cell approaches for multiple sclerosis and amyotrophic lateral sclerosis therapy. Additionally, single‐cell RNA/TCR sequencing of T cells and other immune cells provided insights into immune dynamics in neurodegenerative diseases. This article highlights key findings from the symposium and outlines future research directions to further understand the role of T cells in neurodegeneration, offering innovative therapeutic approaches for AD and other neurodegenerative diseases. Highlights: Researchers gathered to discuss approaches to study T cells in brain disorders. New technologies allow high‐throughput screening of antigen‐specific T cells. Microbial infections can precede several serious and chronic neurological diseases. Central and peripheral T cell responses shape neurological disease pathology. Immunotherapy can induce regulatory T cell responses in neuroinflammatory disorders.